The exposure-reduction part is solid: a full-switching smoker drops the headline cigarette carcinogens by roughly 70 to 95 percent within weeks. The cessation part is the bit that's missing — the most recent Cochrane review couldn't find a single trial that measured whether anyone actually quit smoking using one of these, and every randomised trial in the evidence base was funded by the manufacturer. Three readers have three different answers: a smoker who has failed pharmacy aids and vaping has a real harm-reduction case to consider; a smoker who hasn't worked that ladder should walk it first; a never-smoker is being marketed a nicotine product against nothing on the other side.
A cigarette burns tobacco at about 900 °C and produces more than seven thousand chemicals, including dozens of known carcinogens, tar, and carbon monoxide. An IQOS holder heats a tobacco stick to roughly 320–350 °C with a small ceramic blade — a third of a cigarette's temperature, hot enough to release a nicotine aerosol, cool enough that most of the combustion chemistry doesn't get triggered. The headline numbers are real. Across the harmful-chemical panel the FDA tracks for cigarettes, full-switching smokers drop levels of carcinogens like NNK, benzene, and 1,3-butadiene by 70 to 95 percent within weeks, often approaching never-smoker levels on several of the most-studied markers (Lüdicke et al. 2018) (Mallock et al. 2018).
"Cool enough" is not "cool enough for zero chemistry," though. Independent chemical analyses describe what's happening inside the heat stick as incomplete combustion — a process called pyrolysis — and they find pyrolytic markers, polycyclic aromatic hydrocarbons, and a long tail of carbonyls in the aerosol that the marketing line "heat not burn" elides (Auer et al. 2017). A 2022 chemistry review catalogued eighty constituents that show up at higher levels in heated-tobacco aerosol than in cigarette smoke, including four possible or probable carcinogens (Uguna and Snape 2022). The honest summary isn't safe — it's dramatically less of the chemicals epidemiology has linked to cancer, plus a smaller panel of less-studied chemicals nobody can confidently grade yet.
One more pharmacology detail matters because it shapes the addiction risk: heated tobacco delivers nicotine to the blood faster and at a higher peak than a typical e-cigarette does, closer to a cigarette. That is what makes it a credible substitute for a current smoker — early vapes failed cessation trials partly by under-dosing the nicotine. It is also what makes it dependence-forming in a way that vapes used by never-smokers often aren't: the hit lands fast, in a few minutes, and the brain learns the cue at cigarette speed.
Does it actually help anyone quit?
This is the part the literature is straightforwardly thin on. The Cochrane Collaboration — the gold standard for medical evidence reviews — looked at thirteen studies covering about 2,700 smokers and found something striking: not a single trial reported whether anyone actually quit smoking using these devices. The trials measured exposure reduction and consumer acceptance, the things the manufacturers wanted to demonstrate. They did not measure cessation. And every randomised trial in the evidence base was funded by the manufacturer themselves (Tattan-Birch et al. 2022).
What the published trials do show is the biomarker story: in randomised studies of Japanese smokers asked to switch fully for up to ninety days, urinary NNAL — the dominant biomarker for the lung carcinogen NNK — carboxyhaemoglobin, and biomarkers of benzene, butadiene, and acrolein exposure all dropped roughly 70 to 95 percent compared with continued smoking (Lüdicke et al. 2018). An independent reanalysis of the manufacturer's own data confirmed those exposure drops are real — and added an uncomfortable second finding: on twenty-three of twenty-four biomarkers of biological harm (inflammation, oxidative stress, endothelial function, lung function), the same trials showed no significant difference between IQOS users and continued smokers at six months (St Helen et al. 2018). The exposure dropped. The harm signals, at the time horizon and sample size measured, did not. That gap is the centre of the controversy.
Whether that gap reflects a power problem (six months is short, the trials weren't large), or that nicotine plus the residual aerosol drives a substantial share of cigarette-attributable disease independently, or that the long-term picture will look different — nobody knows yet, because nobody has lived on one of these devices for thirty years. Heated tobacco first hit the Japanese market in 2014. The cancer and cardiovascular-incidence answer for someone who switches in their thirties and stops in their sixties is a question the data physically can't answer for at least another decade.
The population-level signal that does exist is Japan. Heated tobacco's share of total Japanese tobacco sales went from 3 percent in 2016 to 23.5% in 2019; cigarette sales had been declining at about 3 percent a year before IQOS launched, then accelerated to a 16 percent annual decline through 2019 (Cummings et al. 2020). The staggered regional rollout makes a credible natural experiment: cigarette sales began dropping in each Japanese region when IQOS launched there locally, not all at once (Stoklosa et al. 2020). The catch sitting inside that result is that most Japanese heated-tobacco users are also still smoking cigarettes — dual use, not substitution, is the modal lived pattern.
Three readers, three answers
Different starting points produce opposite expected-value calculations on the same device.
If you currently smoke and have failed everything else. The argument here is the same harm-reduction argument that put vaping in U.K. cessation guidelines, weaker. Full substitution — no cigarettes, just the device — measurably reduces your exposure to the chemicals that drive lung cancer, COPD, and a meaningful share of cardiovascular disease (Lüdicke et al. 2018). If you've tried varenicline, tried nicotine-replacement therapy, tried vaping, and you're still on cigarettes, this is the next rung. It is not a guarantee — the disease-endpoint answer doesn't yet exist — but the continued-smoking counterfactual is known severe harm with a measured timeline. Refusing a measured exposure reduction in service of an abstinence-only orthodoxy costs life-years.
If you currently smoke and haven't worked the ladder yet. Don't start here. The cessation evidence for prescription medication (varenicline, bupropion) and for combination nicotine-replacement therapy is solid; the cessation evidence for vaping reached the gold standard in 2024; the cessation evidence for heated tobacco is essentially absent (Tattan-Birch et al. 2022). Walk down the evidence-graded ladder before you reach for the product nobody has measured for the thing you actually want.
If you've never smoked. None of the harm-reduction case is on the table for you. Whatever the long-term cost of using one of these turns out to be — modest, large, somewhere in between — you'd be buying it against nothing. The "reduced exposure" framing is a comparison to a baseline you don't have. And because the nicotine delivery profile is close to a cigarette's, the dependence you'd form would be cigarette-class, not vape-class — fast cue learning, hard exit. The honest answer is the boring one: don't start.
What the marketing softens
"It's smoke-free." The visible cues — no flame, no ash, no glowing ember — make this feel obviously true to a user. The chemistry is less generous. Independent analyses describe what's happening as incomplete combustion of solid tobacco, and they find pyrolytic markers, polycyclic aromatic hydrocarbons, and carbon-rich particulates in the aerosol — the chemical fingerprint of smoke, with most (not all) of the worst stuff turned down (Auer et al. 2017). The "smoke-free" framing has been load-bearing in regulatory arguments for indoor-use exemptions in some places; it is not load-bearing on the chemistry itself.
"The FDA approved it as safer than cigarettes." The FDA did something specific and narrow in 2020: it authorised the manufacturer to make a marketing claim about reduced exposure to specific harmful chemicals, on the basis of the biomarker data. It explicitly did not authorise any claim about reduced risk of disease, and the announcement spelled out: "the FDA's decision today does not mean these products are safe or 'FDA approved'" (FDA 2020). Exposure-reduced is a chemistry claim. Risk-reduced is a disease claim. The agency authorised the first and refused the second. Consumer coverage routinely conflates them; the World Health Organization, looking at the same underlying data, recommends regulating heated tobacco as a conventional tobacco product, with no harm-reduction endorsement at all (WHO 2023).
"It's basically a vape." Different chemistry, different product. A vape heats a propylene-glycol-and-glycerin liquid with no tobacco in it. A heated-tobacco device heats real tobacco and generates an aerosol that sits chemically in the cigarette family — most of the worst constituents turned down, the substrate still tobacco. The cessation evidence base is also asymmetric: vaping is the most strongly evidenced quit aid in modern tobacco research; heated tobacco has essentially none (Tattan-Birch et al. 2022). The marketing positioning is similar; the things they actually do are not the same.
"It doesn't smell." It smells less than cigarettes — no ash, no third-hand residue on fingers and clothes — and frequent users acclimate to the residual odour quickly. People around them don't, particularly indoors. "Much less smell" is true; "no smell" is overclaim.
If you're a smoker considering one
There is no validated quit-with-it protocol because no trial has measured one. The pattern that carries the biomarker-validated evidence — and only the biomarker-validated evidence, not the disease-endpoint evidence — is straightforward.
Where this goes wrong
Three patterns swallow most attempts.
Dual use. You buy the device. You keep smoking — maybe fewer cigarettes, maybe the same number on social occasions and the device indoors. This is the modal pattern in Japan, the largest market, where most heated-tobacco users still smoke cigarettes too (Cummings et al. 2020). The biomarker reductions vanish at even modest concurrent cigarette use. Dual use captures none of the harm-reduction case the product's evidence base actually rests on.
Indefinite continuation. The full switcher who never relapses to cigarettes, never comes off the device. By design this is the harm-reduction outcome, but it is a multi-decade nicotine dependence on an aerosol that did not exist a decade ago. The long-tail safety profile is not knowable yet, and a meaningful share of people who get on these devices appear unlikely to ever come off.
Symbolic substitution. The smoker who buys the device as a hedge — a way to feel as if quitting is in progress without actually doing the thing that quits cigarettes. Treated as a regulatory or social arbitrage (indoor use permitted in more places, fewer comments from coworkers), the device is functioning as cover, not as cessation. The biomarker math is unforgiving about this; the felt sense of progress is not the same as progress.
What changes if you fully switch from cigarettes
The first week, the smell on your clothes and breath stops. Taste and smell partially come back; coffee gets stronger; food gets stronger. Your partner stops mentioning the ashtray. The visible cues — outdoor smoking breaks in the rain, ash on the car seat, the lighter you always need to find — are gone.
By a month or two, the morning cough fades. The flight of stairs to your flat is easier than it had quietly become. Urinary biomarkers for the main lung-cancer-relevant carcinogen drop roughly 70 to 95 percent compared with continued smoking, approaching never-smoker levels for several markers by week 8 to 12 (Lüdicke et al. 2018). Carbon monoxide in your blood drops back to baseline within days, exactly as it would if you had quit cleanly.
By a year, exercise tolerance has rebuilt — partially. People close to you don't see the smoker's face setting in the way it would have. The chronic cardiovascular impacts of continued combustion have been removed from the trajectory, though the device itself still produces measurable acute heart-rate and endothelial effects after each session (Biondi-Zoccai et al. 2019).
By a decade — the part nobody has measured directly — your individual story is one of three. The optimistic version is closer to a full cigarette quitter than to a continued smoker, because the carcinogen exposure was much closer to a quitter's. The pessimistic version is closer to half-way, because of the chronic nicotine and the residual aerosol toxicants nobody fully characterised. Nobody on the planet has been on a heated-tobacco device for thirty years yet; that answer is at least a decade or two off. The asterisk that does not disappear: you are still using nicotine. Most people who switch keep using it for years.
Adjacent territory this entry doesn't cover. Cigarette smoking itself — the substance this is being substituted for, with its own much larger evidence base on disease and cessation. Nicotine vaping, the cessation tool with by far the strongest published evidence and the right next step for most smokers who have failed nicotine-replacement therapy. Prescription cessation medication (varenicline, bupropion) — both with stronger one-year quit outcomes than any inhaled-substitute approach. Nicotine-replacement therapy itself — the patches, gum, lozenges your pharmacy stocks. Smokeless tobacco such as snus, a separate category with its own oral-cancer and cardiovascular profile. And the country-by-country regulatory patchwork — FDA review, the EU's Tobacco Products Directive, Japan's tobacco-product framework, Australia's restrictions — which is the under-discussed reason local availability looks the way it does.
Substance and claimed effects
Heated tobacco products (HTPs) are battery-powered devices that heat — rather than burn — a stick of real tobacco at roughly 300–350°C, generating an inhalable nicotine aerosol without the visible flame, ash, or sustained combustion of a conventional cigarette. The category leader is Philip Morris International's IQOS (HEETS / TEREA tobacco sticks); British American Tobacco markets glo, Japan Tobacco markets Ploom, KT&G markets lil. IQOS is the platform with by far the most published data and is the one the U.S. FDA reviewed under the Modified Risk Tobacco Product (MRTP) pathway. Standard manufacturer claims fall in three buckets: (1) reduced exposure — significantly lower delivery of the harmful and potentially harmful constituents (HPHCs) IARC and the FDA have catalogued for cigarette smoke; (2) reduced harm, by extension — a claim the FDA explicitly declined to authorise (FDA 2020); (3) population substitution — that smokers switching to HTPs accelerates the decline in combustible-cigarette use (Cummings et al. 2020, Stoklosa et al. 2020). This entry covers all of it holistically: the chemistry of the aerosol vs. cigarette smoke, the biomarker-of-exposure data, the acute cardiovascular and respiratory signals, the (genuinely thin) cessation evidence, nicotine dependence and the long-tail safety unknowns, and the asymmetric calculus across never-smokers, current smokers, and the never-quit-the-vape population that already exists for e-cigarettes.
Evidence by addressing question
Mechanism
Science / mechanism. A combustible cigarette burns at roughly 900°C; an IQOS holder heats a tobacco-and-glycerin stick to ~320–350°C via a ceramic blade. The lower operating temperature avoids the bulk of the pyrolytic and combustion chemistry that generates the >7,000 chemicals in cigarette smoke — most carbonyls, polycyclic aromatic hydrocarbons (PAHs), tobacco-specific nitrosamines (NNK, NNN), and carbon monoxide drop by an order of magnitude or more. The German Federal Institute for Risk Assessment (BfR) analysis of THS 2.2 aerosol (the IQOS formulation) reported reductions vs. a 1R4F reference cigarette of >80% for the main carbonyls and >96% for 1,3-butadiene, a major contributor to cigarette-smoke carcinogenicity (Mallock et al. 2018). Public Health England's 2018 evidence review reached an aligned conclusion that HTP aerosol contains "considerably lower" levels of HPHCs than cigarette smoke, while emphasising that >0 is not 0 and long-term data is absent (McNeill et al. 2018).
The independent skeptic literature qualifies this in three ways. (1) Auer et al.'s 2017 JAMA Intern Med chemical analysis detected pyrolytic markers — including PAHs and volatile organic compounds — in IQOS aerosol, arguing the process is incomplete combustion ("pyrolysis"), not "heating without combustion" as marketed (Auer et al. 2017). (2) Uguna and Snape's 2022 review of the chemical evidence catalogued 80 constituents found exclusively or at higher levels in IQOS aerosol than in cigarette smoke, including four possible/probable carcinogens; on a per-mass-of-tobacco basis (IQOS sticks contain 3.2–3.6× less tobacco than a cigarette), tar and nicotine yields per gram of tobacco are actually higher for IQOS — the per-stick reduction is partly a denominator artefact (Uguna and Snape 2022). (3) St Helen et al.'s 2018 independent review of PMI's own MRTP-application data confirmed that biomarkers of exposure to the headline HPHCs were reduced by ~50–90% relative to continued smoking, but that biomarkers of potential harm (inflammation, oxidative stress, endothelial dysfunction) were not significantly different from continued smoking in 23 of 24 measured endpoints (St Helen et al. 2018). Reduced exposure is not the same as reduced harm — the FDA's authorisation language captures exactly that distinction (FDA 2020).
Pharmacokinetically, IQOS delivers nicotine faster and at higher peak plasma concentrations than e-cigarettes typically do, approaching the arterial bolus profile of a combustible cigarette — venous plasma nicotine peaks within 5–8 minutes of use, with peak Cmax roughly 60–80% of a cigarette. This higher delivery rate is what makes IQOS clinically credible as a cigarette substitute (vs. early cig-a-like vapes which under-dosed and failed cessation trials) and is also why dependence formation, withdrawal, and craving in IQOS users tracks closely with cigarette dependence rather than with NRT.
Evidence — does it work as a quit aid
Science. This is the section the cessation literature has the most ground to admit it doesn't yet have. The Cochrane systematic review on heated tobacco products for smoking cessation (Tattan-Birch et al. 2022) included 13 studies (11 RCTs, n=2,666; 2 time-series) and reached a striking finding: no included study reported smoking cessation as an outcome (Tattan-Birch et al. 2022). The RCTs were designed by the manufacturers to demonstrate biomarker-exposure reduction and consumer acceptance, not quit rates. Cochrane's bottom line: insufficient evidence on whether HTPs help people stop smoking; moderate-certainty evidence that switching to HTPs reduces NNAL and carboxyhaemoglobin compared with continued smoking, but levels remain higher than abstinence. Importantly, all included RCTs were industry-funded, which the Cochrane authors flag as a substantial bias-risk concern. This is the cleanest possible contrast with the same Cochrane team's e-cigarette review, which by 2024 reached high-certainty evidence for vaping vs. NRT on the basis of 88 trials and ~27,000 participants — the HTP evidence base is roughly an order of magnitude smaller and one degree of design-rigour weaker on the cessation question itself.
Population / natural-experiment evidence. Japan is the only large-market natural experiment. IQOS launched nationally in 2016; by 2019, HTPs accounted for 23.5% of total tobacco sales (IQOS alone ~17%), having been 2.9% in 2016 (Cummings et al. 2020). Combustible-cigarette sales declined at −3.1% per year in 2011–2015, then accelerated to −16.4% per year in 2016–2019, a roughly five-fold acceleration. Stoklosa et al.'s regional analysis used Japan's staggered rollout as a quasi-experiment, finding that cigarette-sales declines began in each of 11 regions at the timing of local IQOS introduction (Chow tests p<0.001), with the staggered timing predicting decline better than any single national shock or any permutation of the true introduction months (Stoklosa et al. 2020). Both papers are explicit that population sales data describes association, not individual-level substitution, and that the modal Japanese HTP user is a dual-user, not a switcher. Cochrane rated the Japan time-series evidence as "very low certainty" precisely because cigarette sales are an indirect proxy for prevalence and because non-HTP secular factors (tax hikes, indoor-smoking bans, declining initiation) overlap the same window (Tattan-Birch et al. 2022).
Practice / regulatory consensus. No clinical guideline currently recommends HTPs as a smoking-cessation aid in the way Cochrane / NICE recommend e-cigarettes. The U.K. NCSCT and NHS Stop Smoking Services do not include HTPs in licensed cessation pathways. The WHO 2023 report on heated tobacco products explicitly recommends regulating HTPs as conventional tobacco products under the FCTC, with no endorsement as a cessation aid and a warning that the industry framing of HTPs as harm-reduction tools is unsupported by independent evidence on disease endpoints (WHO 2023). The U.S. FDA authorised the IQOS MRTP for "reduced exposure" marketing in July 2020 but specifically declined a "reduced risk" authorisation, and the order does not class IQOS as a cessation product (FDA 2020).
Evidence — cardiovascular effects
Science. The cleanest acute-CV data is the SUR-VAPES 2 randomised crossover trial (Biondi-Zoccai et al. 2019, n=20 healthy smokers, four-way crossover: cigarette, IQOS, e-cigarette, sham). After a single product session, all three nicotine products produced acute elevations in heart rate and blood pressure and acute reductions in flow-mediated dilation. IQOS elevated oxidative-stress markers (NOX2-derived peptide, 8-iso-PGF2α) and reduced endothelial function relative to sham, with magnitude smaller than the cigarette comparator but not zero — closer to e-cigarette than to cigarette (Biondi-Zoccai et al. 2019). Subsequent acute-exposure studies have consistently found IQOS elevates arterial stiffness, pulse-wave velocity, and platelet thrombus formation, with effect magnitudes between sham and cigarette. The systematic-review pattern: differential effects vs. cigarettes are real and in the expected direction; differential effects vs. not using nicotine are also real and small but non-zero.
The independent reanalysis of PMI's own MRTP biomarker-of-potential-harm panel is the most uncomfortable single data point for the reduced-harm hypothesis: across 24 clinically relevant harm markers (lipids, inflammation, oxidative stress, endothelial function, lung function), the PMI 6-month exposure-response trials found no statistically significant difference between IQOS users and continued smokers on 23 of 24 endpoints (St Helen et al. 2018). The exposure dropped substantially; the harm signals, at six months, did not. This may be a power problem (short follow-up, modest n); it may also reflect that nicotine itself and the residual aerosol toxicants drive a substantial fraction of cigarette-attributable CV burden. No long-term incident-MI cohort exists yet — IQOS was first commercialised in Japan in 2014; a fifteen-year incident-cardiovascular-disease answer is at least a decade away.
Evidence — respiratory effects
Science. Spirometric effects of acute IQOS use are modestly worse than sham, modestly better than cigarette use, broadly tracking the e-cigarette acute pattern. Chronic-user observational data is sparse and dominated by Japanese cohorts; the largest series (PMI-funded cohort observational programmes) report fewer respiratory symptoms in switchers than in continued smokers, with no published independent cohort of comparable size. Animal exposure studies — mice exposed to IQOS aerosol for ~24 weeks — show emphysema-pattern alveolar enlargement, oxidative stress, and increased collagen deposition comparable to those produced by cigarette-smoke exposure in matched protocols, though the inhaled-dose extrapolation to human use is uncertain.
PMI's own 6-month ambulatory biomarker-of-exposure trial in Japanese smokers (Lüdicke et al. 2018, n=160 randomised to mTHS / continued mCC / abstinence) reported biomarker reductions of ~50–95% on the headline HPHC panel (NNAL, carboxyhaemoglobin, COHb, 4-aminobiphenyl, benzene, 1,3-butadiene), approaching abstinence levels for several markers (Lüdicke et al. 2018). The respiratory-symptom data from the parallel trial (Lüdicke et al. Part 2, same cohort) and from the BREATHE registry suggests symptom improvement on switching from cigarettes but no return to never-smoker baseline. No long-term cohort exists for COPD incidence in IQOS-only users.
Evidence — cancer / carcinogen exposure
Science. Biomarker-of-exposure data is the strongest evidence in the harm-reduction direction. Urinary NNAL (the dominant biomarker for the lung-carcinogen NNK) is reduced ~70–90% in smokers who fully switch to IQOS in 5- to 90-day confinement / ambulatory trials, often approaching never-smoker levels by week 8–12; equivalent reductions are seen for biomarkers of acrolein, benzene, 1,3-butadiene, 4-aminobiphenyl (Lüdicke et al. 2018, St Helen et al. 2018). The mechanistic case for substantially reduced lung-cancer risk in lifetime full-switchers therefore has a strong proximate-biomarker basis. The cancer-incidence cohort that would close the loop does not exist — solid-tumour latency for tobacco carcinogens is 15–30 years and IQOS has only been on any market since 2014.
The Uguna and Snape 2022 chemical review flags the asymmetric-toxicant question: while the headline FDA HPHC list shows order-of-magnitude reductions, the broader profile includes constituents present at higher levels in IQOS than cigarettes (notably furan, glycidol, some carbonyls under intensive smoking regimens) — some of these have toxicology profiles that haven't been well-characterised for chronic inhalation (Uguna and Snape 2022). The honest framing: dramatically less of the chemicals epidemiology has linked to cancer, plus a small panel of less-studied chemicals that nobody can confidently grade yet.
Protocol
Science / practice. There is no validated protocol for IQOS as a smoking-cessation device because no trial has tested it as one. The empirical use pattern from Japan / Italy / Korea is: a current cigarette smoker buys the device (typically ~$50–100 starter pack with a holder, charger, and one carton of sticks), uses tobacco sticks at roughly the same per-day rate as their prior cigarette consumption, and either substitutes fully, dual-uses, or relapses to cigarettes. Dual use is the modal outcome in observational data — most HTP users in Japan smoke cigarettes concurrently (Cummings et al. 2020). The harm-reduction case is essentially nil for dual users (biomarker reductions disappear with continued cigarette use at >5/day).
For a smoker who is determined to switch and has not been able to with NRT or vaping, the practical pattern that does carry biomarker-validated evidence is: full switch (no cigarettes), 90-day evaluation, and acceptance that nicotine dependence on a new vehicle is the dominant outcome rather than cessation. If full nicotine cessation is the goal, IQOS is not the route — the cessation literature pathway is varenicline + behavioural support, or NRT + behavioural support, or (with stronger evidence) refillable e-cigarettes per the Cochrane vaping verdict.
Contraindications
Science / practice. Pregnancy: nicotine in any form is teratogenic to fetal brain and lung development; ACOG / NICE recommend nicotine-free cessation in pregnancy. Cardiovascular disease: acute heart-rate / BP / vasoconstrictive / endothelial-dysfunction effects of IQOS are smaller than cigarettes but real, and place IQOS in the same caution band as e-cigarettes for unstable angina, recent MI, uncontrolled hypertension, arrhythmia (Biondi-Zoccai et al. 2019). Adolescents: nicotine exposure during ongoing brain development through ~age 25 carries developmental risk that adult exposure doesn't; HTP use in never-smoking adolescents is the population with no plausible benefit and the same dependence risk as cigarettes, given IQOS's near-cigarette pharmacokinetic profile. Established COPD: the harm-reduction case for switching from cigarettes often still favours the switch, but IQOS aerosol is not inert and the symptomatic improvement is partial.
Misconceptions
"It's smoke-free / vapour, not smoke." The marketing leans hard on this — IQOS shows no flame, no sustained ember, no ash. The chemistry is closer to incomplete combustion / pyrolysis than to aerosolised liquid: solid tobacco is being thermally degraded, generating an aerosol that still contains pyrolytic markers (PAHs, levoglucosan), carbon-rich particulates, and carbonyls (Auer et al. 2017, Uguna and Snape 2022). The visible-smoke / visible-fire distinction is a regulatory framing argument (indoor-use exemptions in some jurisdictions), not a chemical one. Calling the emissions "vapour" misrepresents what is actually a smoke-category aerosol with substantially reduced — but non-zero — HPHC content.
"FDA approved it as safer than cigarettes." The 2020 FDA MRTP order authorises marketing claims about reduced exposure to harmful chemicals; it explicitly does not authorise claims about reduced risk of disease, and it does not constitute a finding that IQOS is safer than cigarettes (FDA 2020). The FDA's own language: "Importantly, the FDA's decision today does not mean these products are safe or 'FDA approved.'" The exposure-risk distinction is the entire load-bearing nuance of the order and the most consistently misreported one in consumer-facing coverage.
"It's like a vape." Two products, very different chemistry. Vaping heats a propylene-glycol / glycerin / nicotine liquid at ~150–250°C, no tobacco. HTPs heat real tobacco at 300–350°C and generate a pyrolytic aerosol from tobacco substrate. The chemistry overlaps the cigarette family more than the e-cigarette family. Cessation evidence: vaping is the most strongly evidenced cessation aid in modern tobacco research; HTPs have essentially no cessation evidence base (Tattan-Birch et al. 2022). Pharmacokinetics: IQOS delivers nicotine closer to cigarette than vape. Marketing positioning is similar; the products are not equivalent.
"It doesn't smell." It smells less than cigarettes — no ash, no third-hand-smoke residue on fingers or clothes — but it does have a characteristic odour that frequent users acclimate to and non-users notice. The "no smell" claim is closer to "much less smell, not actually neutral."
Audience — who has which expected-value calculation
Science. Three populations diverge.
Current adult smokers who have failed multiple quit attempts and refuse e-cigarettes: the calculus mirrors the vaping harm-reduction case, weaker. Biomarker-validated full substitution reduces exposure to known carcinogens by 70–95%; if disease incidence tracks biomarker exposure (the standard tobacco-control assumption), substantial harm reduction is plausible but unproven at incidence-endpoint level. Continued smoking has known ~10-year life-expectancy cost; IQOS captures some indeterminate fraction of the recovery a full quit would deliver, smaller than full cessation, almost certainly larger than continued smoking. The cessation-first ladder (varenicline → NRT → vaping → HTP) is the responsible ordering.
Never-smoking adults: any risk above zero is purchased against zero counterfactual benefit. No cessation case applies, the chemistry is not inert, and the pharmacokinetic profile of IQOS produces cigarette-like dependence in naive users. Position: don't start.
Never-smoking adolescents and young adults: the same calculus as never-smoking adults, plus the developmental-vulnerability premium of nicotine on the maturing brain. Adolescent uptake of HTPs in the U.S. has been bounded so far (~1–2% of middle/high schoolers per CDC NYTS) but is meaningfully higher in markets where IQOS is widely available and marketed (Italy, Korea, parts of Japan). The marketing aesthetic — premium hardware, tech-product framing, flavoured sticks — is recognisably the JUUL playbook applied to a tobacco substrate.
Failure modes
Dual use is the dominant failure mode. Japanese surveillance data consistently finds that most HTP users smoke cigarettes too, often more on socially-permitted-smoking occasions and HTP indoors. Biomarker benefits drop sharply with even modest concurrent cigarette use; the cessation literature's "no benefit at five cigarettes a day" finding for vaping appears to apply identically here. Indefinite use — the smoker fully switches, never relapses to cigarettes, never comes off the device. By design this is the harm-reduction outcome, but it is a multi-decade nicotine dependence with a long-tail risk profile no human has fully characterised. Underdosing — choosing IQOS specifically because it's marketed as lower-risk, then finding the nicotine profile insufficient to replace cigarettes and relapsing. The PK profile of IQOS partially mitigates this vs. early vapes, but it is documented in the cessation literature. Symbolic substitution — using IQOS as a hedge while not actually intending to quit cigarettes; treating it as a tax-and-regulation arbitrage rather than a harm-reduction tool.
Practicalities
Cost varies sharply by market. Starter kits: ~$50–100 USD (subsidised heavily by PMI in launch markets). Tobacco sticks (HEETS / TEREA in IQOS terminology): $4–8 per pack of 20 in most markets; pack-a-day use is therefore $30–80/week — roughly on par with or slightly below cigarettes in high-tax jurisdictions (U.K., Australia, Japan), more variable in the U.S. (IQOS was withdrawn from the U.S. market in 2021 following an ITC patent-infringement ruling against PMI's prior U.S. distributor; PMI's reintroduction with revised hardware is in limited rollout). Availability: Japan, Korea, Italy, the U.K., much of continental Europe, and the GCC have established markets; the U.S. is patchy; Australia and several other jurisdictions restrict or ban HTPs. Regulatory framing varies: the U.K. taxes HTPs at a lower rate than cigarettes (harm-reduction stance); the WHO recommends parallel regulation with cigarettes under the FCTC (WHO 2023); the EU TPD has product-specific rules; the FDA reviewed IQOS under the MRTP pathway and authorised reduced-exposure (not reduced-risk) claims for a five-year period that was renewed (FDA 2020).
History
RJR's 1988 Premier and 1996 Eclipse were the first commercial heat-not-burn attempts; both failed commercially, partly due to consumer rejection of the taste, partly to inability to demonstrate harm reduction credibly. PMI's IQOS launched in Nagoya (Japan) and Milan in late 2014, with national Japan rollout in 2016 and rapid market share growth. The product went through holder generations (IQOS 2.4 → 2.4+ → 3 → 3 DUO → ILUMA, the latter using an induction-heating-coil-free design with TEREA sticks). The U.S. FDA MRTP authorisation in 2020 was the second-ever MRTP order (the first was Swedish snus); the renewal in 2024 maintained the reduced-exposure framing. Glo (BAT, 2016), Ploom (JTI), and lil (KT&G) followed PMI into the category. Japan remains the largest single market by some margin; Korea, Italy, Russia (pre-2022) and the U.K. round out the major markets.
Stakes — what continues if a smoker doesn't switch
For the current cigarette smoker, the counterfactual is the full smoking life-expectancy hit: ~10 years off lifetime, dose-linear cardiovascular risk, the cancer panel, COPD. Quitting cleanly recovers most of those years if done before age 50–60. The HTP value proposition for the determined-not-to-quit smoker is to capture some fraction of the cessation gain by removing the combustion chemistry, while keeping the nicotine. The cleanest contrast: not switching is known severe harm with a known trajectory; switching is reduced exposure with partially-characterised long-term risk and continued nicotine dependence. For someone who has serially failed e-cigarette switching, IQOS is plausibly the next harm-reduction rung; for someone who can switch to vaping, the evidence base for vaping is far stronger and the switch is the better-evidenced harm reduction.
Payoff — switching from cigarettes
Felt-experience reports from cessation cohorts and switcher surveys (Japan, Italy): clothes and breath stop smelling like cigarettes within days; the indoor-smoking-ritual costs (going outside, ash, lighters) disappear; morning cough improvement in the 2–8 week range for full switchers, slower than for full cessation. Biomarker timeline: NNAL, COHb, benzene metabolites drop ~70–95% within 5–90 days of full switching, approaching never-smoker levels for several markers by week 12 (Lüdicke et al. 2018, St Helen et al. 2018). Long-term cardiovascular / lung-function / cancer-incidence payoff: directionally favourable on biomarker grounds, unverified on disease grounds, smaller than full cessation. The asterisk that does not disappear: continued nicotine dependence on a new vehicle, with the long-tail exposure profile of an aerosol that hasn't existed long enough to know.
Out of scope (for the reader-facing article)
Combustible-cigarette pharmacology beyond contrast (covered in the smoking entry); cannabis HTPs (different substrate, different chemistry); detailed device-generation taxonomy (IQOS 2.4 vs. 3 vs. ILUMA, glo vs. Ploom vs. lil); jurisdiction-by-jurisdiction regulatory mechanics; the specific FDA PMTA / MRTP procedural mechanics; PMI's broader smoke-free portfolio strategy.
The credibility range
The optimist case. The biomarker-of-exposure evidence is uncontested: full-switching smokers reduce their exposure to dozens of named cigarette carcinogens by 70–95%, approaching never-smoker levels on multiple markers within weeks (Lüdicke et al. 2018, St Helen et al. 2018, Mallock et al. 2018). The FDA — under unusual public scrutiny and a high evidentiary bar — authorised the reduced-exposure claim (FDA 2020). Japan's natural experiment shows cigarette sales accelerating their decline in step with IQOS introduction, with regional staggered-rollout analysis isolating the effect (Stoklosa et al. 2020, Cummings et al. 2020). For a determined-not-to-quit smoker who has failed e-cigarettes, HTPs are the next harm-reduction rung. Refusing to acknowledge measured exposure reduction in favour of an abstinence-only orthodoxy costs preventable life-years in smokers who would have switched.
The skeptic case. No published study has measured smoking cessation as an outcome for HTPs; the Cochrane review found insufficient evidence on whether HTPs help anyone quit (Tattan-Birch et al. 2022). Every RCT in the evidence base was industry-funded; the manufacturers designed and ran the trials that anchor the FDA's reduced-exposure finding. PMI's own 6-month biomarker-of-potential-harm panel showed no significant difference from continued smoking on 23 of 24 clinically relevant markers — the exposure dropped, the harm signals didn't, at least at the time horizon and power level tested (St Helen et al. 2018). The chemistry is incomplete combustion, not "smoke-free" — pyrolytic markers and a long tail of less-studied constituents are present, some at higher levels than in cigarette smoke (Auer et al. 2017, Uguna and Snape 2022). Acute cardiovascular effects (endothelial dysfunction, arterial stiffness, platelet activation) are smaller than cigarettes but real (Biondi-Zoccai et al. 2019). Dual use — the modal outcome in Japan — captures none of the biomarker benefit. The WHO judges the evidence insufficient to endorse HTPs as harm reduction and recommends regulating them as cigarettes (WHO 2023). Long-term cancer / CV / COPD incidence cohorts do not exist; the modern product is too young.
The author's call. The reduced-exposure finding is real and the cessation-evidence absence is real. Both have to coexist in the framing. For a current adult smoker who cannot or will not quit and for whom vaping has failed, IQOS is a defensible harm-reduction step — the biomarker logic is sound, the FDA authorisation is meaningful even within its narrow scope, and the alternative is continued combustion. For an adult smoker who has not tried evidence-based cessation, IQOS is the wrong starting point — varenicline, NRT, and vaping have stronger evidence and (for the first two) no continued tobacco exposure. For a never-smoker, the entry's call is unambiguous: don't start; the chemistry is not inert, nicotine dependence on this vehicle will closely resemble cigarette dependence, and the "reduced exposure" framing only describes a comparison to cigarette smoking the never-smoker isn't doing. Score-relevant: evidence is moderate (3) — biomarker side is strong, cessation side is essentially absent, disease-endpoint side is undecidable; controversy is high (4) because the WHO / FDA / U.K. / Cochrane positions diverge sharply on the same underlying data. Properly framed as action: decide, with the right answer hinging on the reader's smoking status and cessation history.
Stakeholder and incentive map
- PMI and other HTP manufacturers. Strongest commercial interest in the harm-reduction framing. Funded essentially the entire HTP clinical-evidence base. Have built unusually large in-house scientific operations (PMI's R&D Neuchâtel campus); the data is rigorous on its own terms but the funding pattern matters for any institutional weighing.
- Tobacco-harm-reduction camp. The U.K. tobacco-control mainstream that endorses vaping for cessation is more cautious on HTPs, with PHE / OHID acknowledging reduced exposure but stopping short of endorsing HTPs as a cessation route (McNeill et al. 2018). NICE has not added HTPs to cessation guidance.
- Abstinence-only / endgame camp. WHO, U.S. tobacco-control academics, much of European tobacco research outside the U.K. Position: HTPs are a tobacco product, regulate them as such, do not endorse for cessation, do not authorise reduced-risk claims (WHO 2023).
- FDA. Authorised the reduced-exposure MRTP order — substantively constraining on how PMI markets — while explicitly refusing the reduced-risk version (FDA 2020). The narrow authorisation language is the institutional position.
- Independent academic CV / chemistry analysts. St Helen, Glantz, Auer, Mallock-and-BfR, Uguna-and-Snape. Pattern: confirm biomarker-of-exposure reductions, challenge the leap from exposure-reduction to risk-reduction, surface chemistry the manufacturer framing softens.
- Cigarette-manufacturer divided incentive. Same firms make both cigarettes and HTPs (PMI / BAT / JTI / Altria); cannibalisation framing for investors is a different conversation than harm reduction framing for regulators and public health.
Population variability
- Smoking history is the dominant axis. Lifetime smokers (20+ pack-years) who full-switch gain the most on biomarker grounds; never-smokers gain nothing and incur baseline aerosol-and-nicotine risk; dual-users gain essentially nothing.
- Age band. Adolescent brain development through ~25 carries developmental risk for nicotine exposure; the IQOS PK profile produces cigarette-class dependence faster than vape-class.
- Cardiovascular comorbidity. Acute haemodynamic effects make HTPs suboptimal in unstable CV disease, though the harm-reduction case for smokers with established CV disease may still favour switching from cigarettes.
- Mental illness. Smoking rates are 2–3× higher in serious mental illness; switching to HTPs is unlikely to address the underlying dependence and there is no cessation-evidence base in this population.
- Pregnancy. Nicotine in any form is teratogenic; HTPs are not a pregnancy-safe alternative.
- Market / country. IQOS use is heavily Japan-weighted; the evidence base is dominated by Japanese ambulatory cohorts, with all of Japan's specific tobacco-culture, regulatory, and demographic context.
Knowledge gaps
- Cessation-outcome trials. The Cochrane gap — no included study reported smoking cessation as an outcome (Tattan-Birch et al. 2022) — is the most consequential single hole. An independent RCT comparing HTP-as-cessation-aid to NRT or vaping does not yet exist.
- Long-term incident-disease cohorts. No HTP-only population has been followed for >15 years on cancer, CV, or COPD endpoints. The Japan cohort that would generate the first independent answer is now ~10 years in; the answer is at least another decade away.
- Independent (non-PMI-funded) RCTs. Every randomised trial in the Cochrane review was tobacco-industry-funded; an independent confirmation programme exists in early form but is dwarfed by the manufacturer dataset.
- Biomarker-of-potential-harm vs. exposure dissociation. Why did 23 of 24 harm markers fail to differ from continued smoking in PMI's own data (St Helen et al. 2018)? Power, time horizon, nicotine's standalone role, or undetected residual toxicants — unclear, and each implication points to a different long-term-risk forecast.
- Dual-use trajectories. What share of HTP starters move to full substitution, full cessation, or stable dual use over 5 years? The Japanese cohort is large enough to answer this; the question hasn't been cleanly addressed.
- Adolescent gateway. Whether HTP marketing produces cigarette initiation in never-smoking youth, or competes with vaping in the same population, is not yet resolved. The product's near-cigarette PK profile makes the dependence-formation question particularly load-bearing.
- Disposable / next-generation HTP profiles. The chemistry of TEREA (induction-heated, no metallic blade) and the broader next-generation HTP platforms differs from the THS 2.2 base on which most published biomarker data sits; transferability is plausible but unproven.
Narrowing relative to the brief. The brief named four consequences — nicotine addiction, cardiovascular and respiratory health, cancer-related toxicant exposure, and how "reduced exposure" differs from cigarette smoking and from quitting. All four are covered: nicotine addiction in the mechanism section's PK paragraph and in the failure-modes section's indefinite-continuation pattern; cardiovascular markers in the protocol/contraindications warning callout and in payoff; respiratory effects woven into mechanism and payoff; cancer-related toxicant exposure as the dominant evidence-section frame; the reduced-exposure-vs-reduced-risk distinction is the article's load-bearing argument, surfaced in the dek, the evidence section, and the FDA misconception. The audience section makes the asymmetric calculus across never-smokers, current smokers, and the post-everything-else case the spine of the entry.
Hard decisions.
- action = decide, not avoid. Mirrors the vaping entry's call. The right answer is population-dependent (current smoker who has failed cessation vs. current smoker who hasn't vs. never-smoker), and the article's spine is the asymmetric calculus rather than a blanket recommendation. avoid would have erased the harm-reduction case for the smoker who has serially failed cessation; do would have erased the no-counterfactual-benefit case for never-smokers and the ladder-first case for treatable smokers.
- cadence = course. The reader-relevant decision is a 90-day evaluation switch, not steady-state daily use. daily would have mis-signalled chronic substitution as the recommended pattern, which it isn't on the evidence we have.
- Skipped the dream narrative. Overall score ~31 puts the entry below the 40 obligation threshold. The honest hook for this entry is clarity/debunking — the FDA-said-what distinction, the cessation-evidence gap, the WHO/FDA split — and the spec is explicit that forcing a dream onto a clarity entry rings false. The dek and tagline were written straight.
- Foregrounded the cessation-evidence absence. Cochrane's "no trial measured cessation" finding is the single most consequential fact for a smoker considering one of these, and is also the most under-reported in consumer coverage. Put it in the dek and again in the evidence section's opening, in plain language, with the manufacturer-funding disclosure.
- Used the FDA MRTP framing as a teach-the-distinction surface, not a vouching. The exposure-vs-risk authorisation gap is the cleanest illustration of the entire article's argument; the misconceptions section quotes the FDA's own "does not mean these products are safe" line directly.
- Did not lead with the Auer / pyrolysis-as-combustion finding. That argument is real and cited in mechanism + misconceptions, but starting the article on it would have foreclosed the harm-reduction case the smoker-who-has-failed-everything actually has a stake in. The order — biomarkers down, then the long tail of pyrolytic markers and unknown chemicals — mirrors the honest weighting.
Rating difficulties.
- longevity scored 3, not 4. The biomarker-of-exposure data alone would justify a 4 by analogy with cessation. Pulled back to 3 because (a) the disease-endpoint cohort doesn't yet exist, (b) the 23-of-24 harm-marker non-difference (St Helen 2018) is a real signal that exposure reduction may not fully translate, (c) the dominant lived outcome is dual use rather than full switching, (d) the population mix includes never-smokers for whom the score is 0 or negative.
- evidence scored 3, not 4. Biomarker side is strong (4–5 territory by itself); cessation side is a clean Cochrane "insufficient evidence" with zero studies measuring the outcome (1–2 territory); disease-endpoint side is undecidable. 3 is the honest aggregate. Industry funding of the entire RCT base also weighs against a higher score.
- controversy = 4. Easy call. FDA / WHO / U.K. / Cochrane positions diverge sharply on the same data; the gap is foundational (does biomarker exposure reduction warrant any harm-reduction endorsement absent disease-incidence cohorts?), not marginal.
- pull = 4. Premium hardware aesthetic, cigarette-class nicotine PK, less stigmatised than smoking — magnetic in a way the cessation framing of NRT isn't. The honest framing is that the felt rewardingness is part of what makes the product hard to evaluate as harm reduction rather than as a tobacco product.
- applicability = 4. Applied the same "decision-audience for avoid/decide topics" lift as smoking and vaping. Current users are small in most markets; the audience for the decision (do I start? do I let my partner switch? am I being marketed something?) is broad.
Separate-entry candidates.
- Snus and Swedish smokeless tobacco — the original "reduced-exposure tobacco" category, with by far the longest cohort data and the cleanest decoupling from combustion harms; the FDA's only other MRTP authorisation
- Varenicline (Chantix) — first-line prescription cessation pharmacotherapy with stronger one-year evidence than any inhaled substitute
- Combination NRT — patch + short-acting gum/lozenge as the pharmacy-stocked cessation ladder rung
- Nicotine itself — the molecule, separated from its delivery vehicles; relevant across smoking, vaping, HTPs, NRT, gum, and the growing nicotine-pouch category
- Nicotine pouches (Zyn, Velo) — the oral-pouch category that competes with HTPs as a smoke-free tobacco-industry harm-reduction play
Future links. Once the above exist, wire from heated tobacco: (1) into smoking from the dek and audience section; (2) into vaping from the audience ladder and the misconceptions section; (3) into varenicline and NRT from the protocol callout; (4) into snus from out-of-scope; (5) into nicotine pouches from out-of-scope. The current out-of-scope section names smoking, vaping, varenicline/bupropion, NRT, and snus in plain text in advance of the entries existing.
What was kept out. Detailed device-generation taxonomy (IQOS 2.4 → 3 → ILUMA; HEETS vs. TEREA; glo vs. Ploom vs. lil) — would have flattened the article into a product guide and would also age poorly. Country-by-country regulatory mechanics (PMTA, MRTP procedural detail, TPD specifics, Australian prescription model, Japan's specific tobacco-product framework) — named at high level in the out-of-scope and practicalities-equivalent paragraphs of the dossier but not surfaced as article content, because they are a moving target and not load-bearing for the reader's decision. The U.S. import-ban / patent-litigation episode that pulled IQOS off U.S. shelves in 2021–2022 — not relevant to the substance call. PMI's broader "smoke-free portfolio" corporate strategy — adjacent business story, not health content. The Glantz-camp methodological critiques of PMI's cardiovascular reanalyses — surfaced in dossier credibility range but not in the article, since the directional signal (acute CV effects smaller than cigarettes, larger than zero) is already named in the warning callout and payoff.
Heated Tobacco (IQOS)
Minor daily friction — keeping a holder charged, refilling sticks. No active protocol beyond purchase and use; a full-switch attempt adds a short evaluation window but no structured taper.
Starter kits ~$50–100; tobacco sticks $4–8 per pack of 20, putting pack-a-day use at $30–80/week — comparable to cigarettes in most markets, sometimes slightly cheaper in high-tax jurisdictions.
Biomarker-of-exposure reductions of 70–95% for headline carcinogens (NNAL, benzene, 1,3-butadiene, CO) on full switching from cigarettes (Lüdicke et al. 2018; Mallock et al. 2018) imply substantial harm reduction; no long-term incident-disease cohort exists, and 23 of 24 biomarkers of potential harm did not differ from continued smoking at 6 months in PMI's own data (St Helen et al. 2018). Zero or negative effect in never-smokers.
Biomarker-of-exposure side is strong and replicated (Lüdicke et al. 2018; St Helen et al. 2018; Mallock et al. 2018); cessation-outcome side is essentially absent — the Cochrane review (Tattan-Birch et al. 2022) found 13 studies and zero that reported cessation as an outcome; long-term disease-incidence cohorts do not yet exist. All randomised trials in the evidence base are tobacco-industry-funded.
Full-switchers from cigarettes report morning-cough improvement at 2–8 weeks, smell on clothes/breath gone within days, partial restoration of taste/smell; effect smaller and slower than full cessation, and zero for dual users (Lüdicke et al. 2018; St Helen et al. 2018).
For a current smoker who fully substitutes IQOS for cigarettes, the chronic combustion-vasoconstriction-and-staining trajectory halts; long-term facial-aging delta vs. continued smoking is real but mediated through cessation of combustion, not through the HTP itself. Zero benefit for never-smokers.
Acute nicotine alertness effect, similar magnitude to other nicotine vehicles; in ex-smokers, gradual restoration of exercise capacity once combustion exposure ceases. Modest and largely substitution-mediated.
Inhaled nicotine produces a small acute attentional / reaction-time lift; in chronic users the effect is largely withdrawal-relief rather than a true baseline shift, mirroring the cigarette and vape literatures.
Acute nicotine produces a small calming/lift via nAChR-mediated dopamine release; in chronic users this is mostly withdrawal management. Same pattern as cigarettes and vaping.